基于“药用植物亲缘学—分子生物学—活性成分筛选”研究鸡血藤及其混伪品的基原关系
结题报告
批准号:
81960697
项目类别:
地区科学基金项目
资助金额:
34.0 万元
负责人:
张凌
依托单位:
学科分类:
中药鉴定
结题年份:
2023
批准年份:
2019
项目状态:
已结题
项目参与者:
张凌
国基评审专家1V1指导 中标率高出同行96.8%
结合最新热点,提供专业选题建议
深度指导申报书撰写,确保创新可行
指导项目中标800+,快速提高中标率
客服二维码
微信扫码咨询
中文摘要
鸡血藤作为一种具有补血活血、调经止痛、舒筋活络的中药沿用千年,但其基原复杂,亲缘关系不清晰,混伪品(习用品)繁多,导致用药情况混乱,严重影响临床用药的安全有效。本课题基于药用植物亲缘学原理,在传统中药鉴定基础上,考证鸡血藤及混伪品的基原关系,通过DNA条形码序列和叶绿体基因组学,筛选可用于鉴别鸡血藤及混伪品的DNA条形码序列及其组合,明晰鸡血藤各近缘种的基原关系;同时,采用血虚证整体动物模型评价各药材黄酮部位药效,结合指纹图谱构建鸡血藤抗“血虚”的谱效关系,筛选其抗“血虚”的物质基础(质量标志物(群)),从活性成分的角度进一步明晰鸡血藤与混伪品之间相同点与不同点。通过本研究形成基于“药用植物亲缘学—分子生物学—活性成分筛选”的中药基原鉴定新模式,为鸡血藤质量标准提升和替代品种的选取奠定基础。该方法可推广应用于其它中药,为中医药的传承和可持续发展提供科学依据。
英文摘要
Abstract: Spatholobi caulis, as a kind of traditional Chinese medicinewith the activities that enriching blood and promoting blood flow, regulating menstruation and analgesia, relaxing tendons and collaterals, has been used for thousands of years in China, but its original is complex and kinship is not clear, so it mixed with a variety of adulterants (xi supplies), which is leading to drug confusion and seriously affecting the safety and effectiveness of clinical medication.Basing on the theory of pharmacophylogenetics and on the basis of traditional Chinese medicine identification, in this topic we will study the original relationship between spatholobi caulis and its adulterantsthroughDNA Barcodingandchloroplast genomics, to screen the DNA barcode sequences and their combinations for identifyingspatholobi caulis and its adulterants, which could clarify the original relationship of them. At the same time, the whole animal model of blood deficiency syndrome will be used to evaluate the efficacy, and the spectral-effect relationship of spatholobi caulis against "blood deficiency" will be constructed by combining the fingerprint, and the material basis (quality markers (group)) against "blood deficiency" is screened to further clarify the similarities and differences between spatholobi caulis and its adulterants.Through this study, a new identification model of traditional Chinese medicine based on "pharmacophylogenetics -- molecular biology -- active ingredientsscreening" will be formed, which lay a foundation for the improvement of quality standard of spatholobi caulis and the selection of alternative varieties.This method can be applied to other traditional Chinese medicine and provide scientific basis for the inheritance and sustainable development of traditional Chinese medicine.
期刊论文列表
专著列表
科研奖励列表
会议论文列表
专利列表
DOI:DOI:10.1093/jaoacint/qsac119
发表时间:2023
期刊:Journal Of Aoac International
影响因子:--
作者:熊瑶;张凌;杜小浪;王晓云;曹岚;沈昌英;金晨
通讯作者:金晨
DOI:10.7501/j.issn.0253-2670.2023.20.030
发表时间:2023
期刊:中草药
影响因子:--
作者:廖佳伟;金晨;陈志;田晓丹;曾艳丽;何小燕;张凌
通讯作者:张凌
DOI:--
发表时间:2021
期刊:中国实验方剂学杂志
影响因子:--
作者:张庆熙;金晨;陈康;程玉瑶;李洵珣;田晓丹;陈志;项沁;曹光照;张凌
通讯作者:张凌
DOI:--
发表时间:2020
期刊:中草药
影响因子:--
作者:熊瑶;金晨;王晓云;曹岚;杜小浪;李彤;张凌
通讯作者:张凌
DOI:10.12360/cpb202107007
发表时间:2022
期刊:中国药理学通报
影响因子:--
作者:李洵珣;金晨;陈康;程玉瑶;张庆熙;田晓丹;陈志;张凌
通讯作者:张凌
基于TSP1血管新生抑制通路研究丰城鸡血藤黄酮类成分抗RA滑膜血管增生的作用机制及其物质基础
  • 批准号:
    81460595
  • 项目类别:
    地区科学基金项目
  • 资助金额:
    49.0万元
  • 批准年份:
    2014
  • 负责人:
    张凌
  • 依托单位:
国内基金
海外基金